Ambeed.cn

首页 / / / / BI-847325

BI-847325 {[allProObj[0].p_purity_real_show]}

货号:A245078

BI-847325 is a selective and orally bioavailable dual MEK/Aurora kinase inhibitor with IC50 of 3 nM (Xenopus laevis Aurora B), 25 nM (human Aurora A), 15 nM (human Aurora C), 25 nM (human MEK1), and 4 nM (human MEK2) respectively.

BI-847325 化学结构 CAS号:1207293-36-4
BI-847325 化学结构
CAS号:1207293-36-4
BI-847325 3D分子结构
CAS号:1207293-36-4
BI-847325 化学结构 CAS号:1207293-36-4
BI-847325 3D分子结构 CAS号:1207293-36-4
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

BI-847325 纯度/质量文件 产品仅供科研

货号:A245078 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell, 2024, 101755. Ambeed. [ A399663 ]
EMBO J., 2024. Ambeed. [ A295334 ]
JMC, 2024, 67(20): 18265-18289. Ambeed. [ A538667 , A341145 , A117430 , A172297 ]
JMC, 2024. Ambeed. [ A210558 , A1518164 ]
Cell Death Discov., 2024, 10, 436. Ambeed. [ A384235 ]
更多 >
产品名称 Aurora A Aurora B Aurora C 其他靶点 纯度
BI-847325 ++

Aurora A (Human), IC50: 25 nM

++++

Aurora B (Xenopus laevis), IC50: 3 nM

++

Aurora C (Human), IC50: 15 nM

99%+
CCT 137690 ++

Aurora A, IC50: 15 nM

++

Aurora B, IC50: 25 nM

++

Aurora C, IC50: 19 nM

99%+
MK-5108 ++++

Aurora A, IC50: 0.064 nM

99%+
KW-2449 +

Aurora A, IC50: 48 nM

FLT3 99%+
Tozasertib ++++

Aurora A, Ki app: 0.6 nM

++

Aurora B, Ki app: 18 nM

+++

Aurora C, Ki app: 4.6 nM

FLT3,Bcr-Abl 99%+
AT9283 ++++

Aurora A, IC50: ~3.0 nM

++++

Aurora B, IC50: ~3.0 nM

99%+
MLN8054 +++

Aurora A, IC50: 4 nM

+

Aurora B, IC50: 172 nM

99%+
ZM-447439 +

Aurora A, IC50: 110 nM

+

Aurora B, IC50: 130 nM

Src 99%+
TCS7010 ++++

Aurora A, IC50: 3.4 nM

99%+
TAK-901 ++

Aurora A-TPX2, IC50: 21 nM

++

Aurora B-INCENP, IC50: 15 nM

99%+
Danusertib +++

Aurora A, IC50: 13 nM

+

Aurora B, IC50: 79 nM

+

Aurora C, IC50: 61 nM

RET 99%+
MK-8745 ++++

Aurora A, IC50: 0.6 nM

99+%
PHA-680632 ++

Aurora A, IC50: 27 nM

+

Aurora B, IC50: 135 nM

+

Aurora C, IC50: 120 nM

FLT3 99%+
AMG 900 +++

Aurora A, IC50: 5 nM

+++

Aurora B, IC50: 4 nM

++++

Aurora C, IC50: 1 nM

99%+
Alisertib ++++

Aurora A, IC50: 1.2 nM

99%+
ENMD-2076 +++

Aurora A, IC50: 14 nM

+

Aurora B, IC50: 350 nM

FLT3,RET 98%
JNJ-7706621 +++

Aurora A, IC50: 11 nM

++

Aurora B, IC50: 15 nM

99%+
CYC-116 +++

Aurora A, Ki: 8 nM

+++

Aurora B, Ki: 9 nM

FLT3 99%+
Reversine +++

Aurora A, IC50: 12 nM

+++

Aurora B, IC50: 13 nM

++

Aurora C, IC50: 20 nM

98%
CCT129202 ++

Aurora A, IC50: 42 nM

+

Aurora B, IC50: 198 nM

+

Aurora C, IC50: 227 nM

98%
SNS-314 mesylate +++

Aurora A, IC50: 9 nM

++

Aurora B, IC50: 31 nM

++++

Aurora C, IC50: 3 nM

99%+
Barasertib-HQPA ++++

Aurora B, IC50: 0.37 nM

99%+
Hesperadin +

Aurora B (human), IC50: 250 nM

98%
GSK-1070916 ++++

Aurora B-INCENP, IC50: 3.5 nM

+++

Aurora C-INCENP, IC50: 6.5 nM

SIK,Tie-2 99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 MEK MEK1 MEK1/2 MEK2 MEK5 其他靶点 纯度
Honokiol 98%
Mirdametinib ++++

MEK, IC50: 0.33 nM

99%+
Binimetinib +++

MEK, IC50: 12 nM

99%+
BI-847325 ++

MEK1, IC50: 25 nM

+++

MEK2, IC50: 4 nM

99%+
U0126-EtOH +

MEK1, IC50: 0.07 μM

++

MEK2, IC50: 0.06 μM

98%
GDC-0623 ++++

MEK1, IC50: 0.13 nM

99%+
TAK-733 ++++

MEK1, IC50: 3.2 nM

99%+
Trametinib ++++

MEK1, IC50: 0.92 nM

++++

MEK2, IC50: 1.8 nM

99%+
Selumetinib +++

MEK1, Kd: 99 nM

MEK1, IC50: 14 nM

+

MEK2, Kd: 530 nM

99%+
CI-1040 ++

MEK1, IC50: 17 nM

++

MEK2, IC50: 17 nM

99%+
Myricetin 98%
Refametinib ++

MEK1, IC50: 19 nM

++

MEK2, IC50: 47 nM

99%+
Cobimetinib +++

MEK1, IC50: 4.2 nM

99%+
PD98059 +

MEK1, IC50: 2 μM

99%+
SL327 +

MEK1, IC50: 0.18 μM

+

MEK2, IC50: 0.22 μM

AP-1 98+%
PD318088 98%
AZD8330 +++

MEK1/2, IC50: 7 nM

99%+
Pimasertib 98%
(E/Z)-BIX02189 ++++

MEK5, IC50: 1.5 nM

99%+
(E/Z)-BIX02188 +++

MEK5, IC50: 4.3 nM

99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

BI-847325 生物活性

靶点
  • Aurora A

    Aurora A (Human), IC50:25 nM

  • Aurora B

    Aurora B (Xenopus laevis), IC50:3 nM

  • Aurora C

    Aurora C (Human), IC50:15 nM

  • MEK2

    MEK2, IC50:4 nM

  • MEK1

    MEK1, IC50:25 nM

描述 Three Homologous Aurora kinases (AK-A, -B, and -C) have overlapping effects on the cell cycle, in particular cytokinesis. AK-A has been implicated in mitotic entry, separation of centriole pairs, bipolar spindle assembly, and alignment of metaphase chromosomes. AK-B is involved in chromosomal biorientation, regulating the association between kinetochores and microtubules, and phosphorylates histone H3 (HH3) which aids chromatin condensation and separation[3]. BI-847325 is an ATP-competitive dual inhibitor of MEK and Aurora kinases with IC50s of 25, 3 and 15 nM for Aurora A, B, and C respectively. BI-847325 can potently inhibit MEK1/2 and Aurora A/B kinases. In a vitro study, C643 cell line was collected, cultured and treated with 15 μM and 34 μM concentrations of BI-847325 for 48 h. MALAT1 gene expression, following BI-847325 treatment was determined and the result showed that the expression of MALAT1 in C643 (p < 0.01) cell line was significantly decreased in comparison with untreated control, suggesting that BI-847325 which inhibits Aurora kinase family could be effective against cancer by regulating the genes involved in cell cycle and apoptosis including MALAT1 and its downstream genes[3]. And in another vitro study, a enzyme, ATP and kinase buffer mixture (30 mL) was added to 10 μL BI-847325 solution for 15 min at room temperature. and 10 mL of peptide mixture was added subsequently for 1 h at room temperature then reaction was stopped for calculation of IC50 values and measurement of Incorporated phosphate, suggesting that BI-847325 possess potent activity for Aurora kinases inhibition. In a cell-cycle analysis, A375 and Calu-6 cell lines were treated with BI-847325 at dose of 50 and 500 nM for 48 h. After fixing and staining, cells were performed cell cycle analysis, indicating that cells treated with BI-847325 at low concentration (50 nM) showed a high percentage of cells in G2–M and polyploid/multinucleated states and low proportion in G1 phase and at high concentrations (500 nmol/L), the proportion of cells in G1 decreased further whereas that in G2–M and polyploid/multinucleated states increased. The result showed that BI-847325 acts as a dual MEK and Aurora kinase inhibitor in these two cell lines. In a vivo study, bearing A375 (BRAFV600E) xenografts mice were orally treated at 10 mg/kg of BI-847325 daily for 10 days. Marked inhibition of MEK and ERK phosphorylation in tumors was observed 2 hours after the last dosing[4].
作用机制 BI-847325 is located in the ATP-binding pocket in the hinge region of both kinases and thus acts as an ATP-mimetic[4].

BI-847325 动物研究

Dose Mice: 10 mg/kg/q.d., 20 mg/kg/q7d[2] (p.o.), 70 mg/kg/week[1] (p.o.)
Administration p.o.
Pharmacokinetics
Animal Mice[2]
Dose 10 mg/kg
Administration p.o.
Cmax 377 ± 87 nmol/L
AUC 3700 ± 1600 nmol·h/L

BI-847325 参考文献

[1]Phadke MS, Sini P, et al. The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression. Mol Cancer Ther. 2015 Jun;14(6):1354-64.

[2]Sini P, Gürtler U, et al. Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases. Mol Cancer Ther. 2016 Oct;15(10):2388-2398. Epub 2016 Aug 5.

[3]Samimi H, Haghpanah V, Irani S, Arefian E, Sohi AN, Fallah P, Soleimani M. Transcript-level regulation of MALAT1-mediated cell cycle and apoptosis genes using dual MEK/Aurora kinase inhibitor "BI-847325" on anaplastic thyroid carcinoma. Daru. 2019 Jun;27(1):1-7.

[4]Sini P, Gürtler U, Zahn SK, Baumann C, Rudolph D, Baumgartinger R, Strauss E, Haslinger C, Tontsch-Grunt U, Waizenegger IC, Solca F, Bader G, Zoephel A, Treu M, Reiser U, Garin-Chesa P, Boehmelt G, Kraut N, Quant J, Adolf GR. Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases. Mol Cancer Ther. 2016 Oct;15(10):2388-2398.

BI-847325 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.15mL

0.43mL

0.22mL

10.76mL

2.15mL

1.08mL

21.53mL

4.31mL

2.15mL

BI-847325 技术信息

CAS号1207293-36-4
分子式C29H28N4O2
分子量 464.558
别名
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Keep in dark place,Sealed in dry,2-8°C

溶解度

DMSO: 16 mg/mL(34.44 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。